This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis
by Zacks Equity Research
Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.
Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS
by Zacks Equity Research
Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.
AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study
by Zacks Equity Research
AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.
Down 24.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Viking Therapeutics, Inc. (VKTX)
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bristol Myers (BMY) sBLA for Reblozyl Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.
Novartis (NVS) Highlights Growth Profile at its R&D Day
by Zacks Equity Research
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down
by Zacks Equity Research
Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.
Bristol Myers (BMY) Top Drugs Maintain Momentum Amid Competition
by Zacks Equity Research
Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.
Bristol Myers (BMY) Zeposia Gets EC Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.
Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU
by Zacks Equity Research
Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.
Bristol Myers' (BMY) Cardiovascular Drug Review Extended by FDA
by Zacks Equity Research
Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.
Wall Street Analysts Think Viking Therapeutics, Inc. (VKTX) Could Surge 226%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 225.8% in Viking Therapeutics, Inc. (VKTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Viking Therapeutics, Inc. (VKTX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.
How Much Upside is Left in Viking Therapeutics, Inc. (VKTX)? Wall Street Analysts Think 204%
by Zacks Equity Research
The consensus price target hints at a 204.1% upside potential for Viking Therapeutics, Inc. (VKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
Gilead (GILD) Expands NASH Collaboration With Novo Nordisk
by Zacks Equity Research
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.
Intercept (ICPT) Posts New Positive Results on NASH Drug
by Zacks Equity Research
Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.
Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.
Intercept Slumps as the FDA Issues CRL to NASH Candidate
by Zacks Equity Research
Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
NASH Scorecard So Far This Year: A Look at the Hits & Misses
by Ekta Bagri
NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.